|
|
|
| Clinical effect of Calcitriol on early type 2 diabetic nephropathy |
| HUANG Cheng1 SHAO Yunxia2 WU Yan2 XING Changying1▲ |
1.Department of Nephrology, the First Affiliated Hospital of Nanjing Medical University Jiangsu Provincial Hospital, Jiangsu Province, Nanjing 210029, China;
2.Department of Nephrology, Wuhu Second People’s Hospital, Anhui Province, Wuhu 241000, China |
|
|
|
|
Abstract Objective To observe the clinical effect of Calcitriol on early type 2 diabetic nephropathy. Methods A total of 90 type 2 diabetic nephropathy patients admitted to the First Affiliated Hospital of Nanjing Medical University and the Wuhu Second People’s Hospital from August 2019 to May 2022 were selected as the study objects, and they were divided into two groups by random number table method， with 45 cases in each group. The control group received Olmesartan Ester on the basis of conventional treatment, and the observation group received Calcitriol on the basis of the control group, the treatment course of both groups was eight weeks. Renal function (serum creatinine [Scr], urinary albumincreatinine ratio [UACR], microalbuminuria [MA], cystatin C [CysC]), alkaline phosphatase (ALP), blood pressure (diastolic blood pressure [DBP], systolic blood pressure [SBP]), blood glucose (fasting blood glucose [FBG], glycated hemoglobin [HbA1c]), NADPH Oxidase 4 (NOX4) of the two groups were compared before and after treatment, the efficacy and incidence of adverse reactions were compared between the two groups. Results After treatment, Scr, UACR, MA, CysC in both groups, and ALP in control group were lower than those before treatment, and Scr, UACR, MA, CysC in observation group were lower than those in control group (P＜0.05). The ALP in the observation group was higher than that before treatment, and the observation group was higher than that in the control group (P＜0.05). After treatment, SBP, DBP, FBG and HbA1c in both groups were decreased compared with those before treatment (P＜0.05), and there was no statistical significance between groups (P＞0.05). After treatment, urine NOX4 decreased in both groups compared with that before treatment, and the observation group was lower than the control group (P＜0.05). The efficacy of the observation group was better than that of the control group(P＞0.05). There was no significant difference in the total rate of adverse reactions between the two groups (P＞0.05). Conclusion Calcitriol in the treatment of early type 2 diabetic nephropathy patients can significantly reduce the renal function damage, the degree of interphase podocyte damage, and improve the efficacy.
|
|
|
|
|
|
[1] 朱艺平，陈一平，赵艳英，等.针刺治疗2型糖尿病肾病周围神经病变的临床观察[J].广州中医药大学学报，2023，40（4）：899-904.
[2] 王立梅，薛长春，吴震宇.血糖波动与2型糖尿病肾病的相关性研究[J].中华保健医学杂志，2023，25（1）：70-72.
[3] 饶佳欣，谢宁，何仁栋，等.可溶性白细胞抗原93在2型糖尿病肾病中的临床价值研究[J].川北医学院学报，2023，38（3）：309-313.
[4] 苏比努尔·艾尔肯，李静.血清尿酸与2型糖尿病肾病的相关性分析[J].中国现代医生，2022，60（14）：82-85.
[5] 李昌艳，刘娟，顾芳，等.2型糖尿病患者进展为早期糖尿病肾脏病的影响因素分析[J].中国全科医学，2020，23（26）：3291-3296.
[6] 李敬敬，金国玺.2型糖尿病肾病与血清Netrin-1水平的关联分析[J].河北医学，2022，28（5）：789-793.
[7] 常杰.血清视黄醇结合蛋白与尿微量白蛋白在2型糖尿病早期肾病中的诊断价值探讨[J].中国全科医学，2020， 23（2）：132-133.
[8] 滕雅芹，徐鑫淼，郑丽红，等.西格列汀片联合黄葵胶囊治疗早期糖尿病肾病效果观察及对CysC，Hcy，mALB的影响[J].中华中医药学刊，2021，39（11）：251-254.
[9] Esmaile SC，Bezerra KS，Melo D，et al. Quantum binding energy features of the drug olmesartan bound to angiotensin type-1 receptors in the therapeutics of stroke [J]. New Journal of Chemistry，2021，45（41）：19487-19496 .
[10] Laura MA，Sara P，Cristina AM，et al. Effects of calcitriol and paricalcitol on renal fibrosis in CKD [J]. Nephrol Dial Transplant，2021，36（5）：793-803.
[11] 中华医学会糖尿病学分会微血管并发症学组.糖尿病肾病防治专家共识（2014年版）[J].中华糖尿病杂志，2014， 6（11）：792-801.
[12] 王静，赵红敏，张宇，等.血清25-羟维生素D3水平与2型糖尿病肾病患者并发肌少症的相关性分析[J].中国医刊，2023，58（3）：333-336.
[13] 万红波，郑永丽，郑栓，等.益肾化湿颗粒对2型糖尿病肾病大鼠肾功能的影响[J].中国中西医结合肾病杂志，2022，23（2）：130-132.
[14] 何晓玮，钟涛.α硫辛酸辅助奥美沙坦酯对糖尿病肾病患者血清miR-150-5p及miR-155-5p表达的影响[J].中国现代应用药学，2021，38（5）：624-629.
[15] 陈年由，林小波.奥美沙坦酯片致急性肾衰期1例[J].中国药师，2022，25（7）：1225-1226.
[16] 王春艳，张金卉，张洁，等.骨化三醇对糖尿病周围神经病变疗效评价的研究[J].中国糖尿病杂志，2021，29（10）：758-762.
[17] 徐台林，蒋成燕，陈袁，等.老年糖尿病肾病患者并发高尿酸血症影响因素[J].中国老年学杂志，2022，42（19）：4649-4652.
[18] Zhuang Y，Song J，Ying M，et al. Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to met- formin in patients with type 2 diabetes：A meta-analysis [J]. Medicine，2020，99（30）：e21409.
[19] Luan F，Chen Y，Xu Y，et al. Associations between whole blood trace elements concentrations and HbA1c levels in patients with type 2 diabetes [J]. BioMetals，2022，35（5）：1011-1022.
[20] 章晓良，程莉，吴福杉，等.骨化三醇联合奥美沙坦酯治疗早期T2DN的效果及其对肾脏足细胞损伤机制的研究[J].国际泌尿系统杂志，2022，42（6）：1080-1084.
[21] 黄程，邵云侠，吴艳，等.骨化三醇联合奥美沙坦酯治疗早期2型糖尿病肾病的效果及对肾病足细胞损伤的机制探讨[J].中国医药导报，2022，19（15）：79-82.
[22] 王小剑，谢先红，罗驰.血清ALP水平预测急性失代偿性心力衰竭并发肾功能恶化的价值[J].山东医药，2020， 60（22）：27-30.
[23] 俞刚，陆峰泉，沈静，等.2型糖尿病肾病患者血清同型半胱氨酸，叶酸和亚甲基四氢叶酸还原酶基因多态性的关系[J].中华核医学与分子影像杂志，2021，41（3）：145- 148.
[24] 陈久应，徐新润，宰国田，等.2型糖尿病患者血浆低密度脂蛋白亚型水平与糖尿病肾病的相关性[J].中国临床研究，2023，36（3）：445-449.
[25] 黄程，邵云侠，吴艳，等.骨化三醇联合奥美沙坦酯治疗早期2型糖尿病肾病的效果及对肾病足细胞损伤的机制探讨[J].中国医药导报，2022，19（15）：79-82.
[26] 李黎.血清1，25-二羟维生素D3超敏C反应蛋白与2型糖尿病肾病的相关性研究[J].中国药物与临床，2020， 20（18）：3039-3041.
[27] 李坤浪，陈滨，钟伟章.缬沙坦不同使用时限对2型糖尿病肾病患者尿微量白蛋白排泄率和肾血流动力学的影响[J].中国医药科学，2021，11（1）：130-133.
[28] 周梦文，杨杨，卢从群，等.维生素D受体在糖尿病肾病足细胞损伤及蛋白尿缓解中的作用[J].中华肾脏病杂志，2020，36（5）：385-393. |
|
|
|
